HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

human 1a alloantigen (HPA-1a)

Subscribe to New Research on human 1a alloantigen

HPA-1a is an allele of platelet glycoprotein IIIa; immunization of mother in pregnancy against PL(A1) implicated in cause of neonatal alloimmune thrombocytopenia

Also Known As:

HPA-1a; 1a alloantigen, human; PL(A1) antigen, human; PLA1 alloantigen, human; PLA1 antigen, human; Pl(A) alloantigen, human; Zw(a) antigen, human; human platelet antigen 1a; platelet specific antigen PL(A), human; platelet specific antigen PL(A1), human

Networked: 77 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Biological Factors: 1315
- Antigens: 114404
  - Isoantigens: 1094
    - Human Platelet Antigens: 92
      - human 1a alloantigen: 77

Experts

1.	Santoso, Sentot: 7 articles (07/2013 - 12/2005)
2.	Ouwehand, Willem H: 6 articles (07/2013 - 04/2004)
3.	Bein, Gregor: 5 articles (07/2013 - 08/2007)
4.	Williamson, Lorna M: 5 articles (07/2013 - 04/2004)
5.	Bakchoul, Tamam: 4 articles (07/2013 - 08/2007)
6.	Ghevaert, Cedric: 4 articles (07/2013 - 05/2007)
7.	Ouwehand, W H: 3 articles (08/2013 - 11/2007)
8.	Armour, Kathryn L: 3 articles (07/2013 - 04/2004)
9.	Allen, Dave: 3 articles (02/2010 - 05/2007)
10.	Kroll, Hartmut: 3 articles (05/2009 - 12/2005)

Related Diseases

1.	Neonatal Alloimmune Thrombocytopenia 05/01/2003 - "The purpose of the study was to determine the prevalence of the HPA-1a negative platelet phenotype in a cohort of pregnant women in Ireland, the rate of alloimmunisation to HPA-1a in HPA-1 mismatched pregnancies and the associated incidence of neonatal alloimmune thrombocytopenia. " 07/01/2012 - "Would it be possible to prevent HPA-1a alloimmunization to reduce the incidence of fetal and neonatal alloimmune thrombocytopenia?" 10/01/2011 - "Noninvasive fetal HPA-1a genotyping offers a safe method for alloimmunised pregnant women to determine whether their fetus is at risk of fetal or neonatal alloimmune thrombocytopenia (FNAIT) and whether interventions to prevent intracranial haemorrhage are required. " 05/01/2003 - "Three of 34 (9%) women who delivered HPA-1a positive babies had detectable anti-HPA-1a and all three babies had neonatal alloimmune thrombocytopenia, for an overall incidence of 1:1100 non-selected pregnancies. " 06/01/2001 - "Fetal and neonatal alloimmune thrombocytopenia (AIT) caused by feto-maternal incompatibility at the HPA-1a (PLA-1) locus is well characterized. "
2.	Purpura 07/01/2004 - "Efficacy of HPA-1a (PlA1)-negative platelets in a patient with post-transfusion purpura." 10/01/1991 - "However, in vitro studies demonstrated that the patient's platelets were negative for HPA-1a and that anti-HPA-1a was present in the serum, both of which findings were consistent with the diagnosis of posttransfusion purpura. " 08/01/2007 - "HPA-1a serum samples derived from mothers with NAIT (n = 36) and from posttransfusion purpura patients (n = 2) as well as HPA-1b (n = 4), HPA-5b (n = 2), HPA-3a (n = 4), and HLA Class I (n = 2) alloantiserum samples from multitransfused patients were investigated in GASA and MAIPA assays. " 01/01/1996 - "Blood components--transfusion support in post-transfusion purpura due to HPA-1a Immunization." 08/01/1995 - "Cases of alloimmunization to HPA-1a and HPA-1b resulting in refractoriness to transfused platelets and the subsequent development of a posttransfusion purpura-like syndrome are reported. "
3.	Thrombocytopenia (Thrombopenia) 11/16/1999 - "Immunological study of the platelets from the patients with aloimmune thrombocytopenia showed the absence of HPA-1a in their mothers. " 06/01/1995 - "This study describes a pilot prospective screening programme for the antenatal detection of fetomaternal alloimmune thrombocytopenia (FMAIT) due to HPA-1a incompatibility. " 07/18/2013 - "Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers." 07/18/2013 - "Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia." 02/01/2009 - "Blockade of maternal anti-HPA-1a-mediated platelet clearance by an HPA-1a epitope-specific F(ab') in an in vivo mouse model of alloimmune thrombocytopenia."
4.	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/01/2015 - "This condition, which most commonly results from incompatibility between the mother and the fetus for the Human Platelet Antigen-1a (HPA-1a), may lead to intracranial hemorrhage, damage of the central nervous system (CNS) and even death of the fetus or the newborn. " 09/01/2000 - "The greatest clinical challenge relates to the antenatal management of pregnant women alloimmunized to the HPA-1a (P1A1, Zwa) antigen, and particularly the subset of such women who have a history of a previously affected infant with severe thrombocytopenia and/or intracranial hemorrhage (ICH). " 08/01/2008 - "As a potential treatment to prevent fetal intracranial hemorrhage in HPA-1a alloimmunized pregnancies, we generated an antibody that blocks the binding of maternal HPA-1a-specific antibodies to fetal HPA-1a1b platelets by combining a high-affinity human HPA-1a-specific scFv (B2) with an IgG1 constant region modified to minimize Fcgamma receptor-dependent platelet destruction (G1Deltanab). "
5.	Thrombocytopenic Purpura (Thrombopenic Purpura) 11/01/1995 - "Most severe episodes of neonatal alloimmune thrombocytopenic purpura (NATP) are caused by antiplatelet alloantibodies against the HPA-1a (PlA1) antigen. " 06/01/1992 - "Antibodies to the platelet HPA-1a antigen can elicit in the newborn a condition known as neonatal alloimmune thrombocytopenic purpura (NAITP). " 06/01/1998 - "The rare neonatal alloimmune thrombocytopenic purpura (NAITP) are caused by IgG alloantibodies against HPA-1a in 75-90%, HPA1b in 3-5%, HPA 3a in 4-5%, HPA5b in 6-19% and against private platelet antigens in 3%. "

Related Drugs and Biologics

1.	DNA (Deoxyribonucleic Acid)
2.	Antibodies
3.	Antigens
4.	Isoantibodies
5.	Immunoglobulin G (IgG)
6.	Immunoglobulins (Immunoglobulin)
7.	Human Platelet Antigens
8.	Isoantigens (Alloantigen)
9.	Glycoproteins (Glycoprotein)
10.	HLA-DRB3 (HLA DRB3)

Related Therapies and Procedures

1.	Stem Cell Transplantation
2.	Platelet Transfusion (Blood Platelet Transfusions)